Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study -

Two injections of CoV2 preS dTM-AS03 showed acceptable safety and reactogenicity, and robust immunogenicity in adults who were SARS-CoV-2 naive and non-naive. These results

1486254963391184896

The Lancet Infectious Diseases

New research Article: Safety and immunogenicity of an AS03-adjuvanted #SARSCoV2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study https://t.co/pVNMOd65Mx #COVID19 - view on twitter

More coverage: #covid19 #SARSCoV2

Read the full article here

See more from The Lancet Infectious Diseases